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Anaemia is a cardinal feature in patients with bacterial 
infections, particularly infections lasting longer than a month. 
It occurs with a wide spectrum of infections, especially 
tuberculosis, chronic pyogenic infections, osteomyelitis, 
pneumonia, subacute bacterial endocarditis, pulmonary 
abscesses, empyema, cellulitis and chronic urinary tract 
infection.1 Anaemia is present in most patients with active 
pulmonary tuberculosis.2 The anaemia occurs as a result of 
immune stimulation, and is common to all inflammatory 
disease. Originally termed the ‘anaemia of infection’, it 
was subsequently included within the ‘anaemia of chronic 
disease’, and is now regarded as an example of the ‘anaemia of 
inflammation’. For more detailed information on the anaemia 
of infection and the anaemia of chronic disease, the reader is 
referred to two recent comprehensive reviews.3,4 
Pathogenesis
The anaemia of infection (AI) is probably an essential 
protective response to chronic infection. It reflects activation of 
the immune system designed to withhold iron from invading 
pathogens. Bacteria require iron as an essential element for 
survival and normal growth, due to its role in mitochondrial 
respiration. The AI is mediated by cytokines, the action of 
which withholds iron from the marrow, directly depresses 
erythropoiesis and damages red cells, all of which result in 
anaemia. A further factor could be erythrophagocytosis, but 
this is unlikely to contribute significantly to the anaemia, 
except perhaps in the haemophagocytic syndrome.
The role of cytokines in the anaemia of 
infection
Cytokines produced as mediators of the host immune response 
to infection are responsible for the development of the AI. 
Cytokines are proteins released by one cell population on 
contact with specific antigen, and act as intercellular mediators 
in the generation of an immune response. The invasion of 
bacteria leads to activation of T-lymphocytes and macrophages, 
which induce the production of the cytokines interferon-
gamma (INF-γ), tumour necrosis factor-alpha (TNF-α), 
interleukin-1 (IL-1) and interleukin-6 (IL-6). IL-6 stimulates the 
hepatic synthesis of hepcidin,5,6 the effect of which is to divert 
iron into stores rather than release, resulting in iron-restricted 
erythropoiesis and anaemia. 
Cytokines also impair red cell production in the marrow.  
IL-1 and TNF-α inhibit the production of erythropoietin 
(Epo), and together with INF-γ impair responsiveness of 
progenitor cells to Epo.7 An inhibitory effect of TNF-α on red 
cell production in the bone marrow has been demonstrated 
by both in vitro and in vivo studies. INF-γ directly suppresses 
the proliferation of erythroid progenitor cells. In this way, 
cytokines impair the physiological Epo response to the 
anaemia. In addition, TNF-α directly damages erythrocytes and 
decreases red cell life span.
In infection, cytokines and their products therefore cause: 
(i) a diversion of iron into iron stores in the RES, resulting 
in decreased iron concentration in the plasma, thus limiting 
its availability to red cells for haemoglobin synthesis; (ii) an 
inhibition of erythroid progenitor cell proliferation; and (iii) 
inappropriate production and activity of Epo.8 The first leads 
to anaemia and the latter two result in suboptimal response of 
the bone marrow to the anaemia. AI is therefore basically an 
underproduction anaemia due to iron restriction, combined 
with inability of erythropoiesis to compensate adequately for 
the anaemia. Reduced red cell survival is an additional, but less 
important factor in the genesis of the anaemia. The cytokine-
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induced reduction in the availability of iron together with the 
decreased production of and response to Epo are the major 
factors in the development of AI.
Iron metabolism in infection
Humans have developed defence mechanisms to withhold 
iron from bacteria, which grow faster when iron is abundant. 
Infections induce iron sequestration in macrophages, and 
also decrease iron absorption from the small intestine. This 
probably limits iron availability to invading bacteria, thereby 
containing the infection, and as such is part of the body’s 
immune mechanism.9 This diversion of iron to stores is due to 
the action of cytokines on the iron-regulating peptide, hepcidin. 
Hepcidin is synthesised in the liver, released into the plasma 
and excreted in the urine.10 It is the dominant regulator of the 
absorption of dietary iron, its release from macrophages, and 
mobilisation from hepatic stores. 
Hepcidin synthesis is rapidly induced by the cytokine 
IL-6, which is produced at the site of infection. Hepcidin 
concentration increases in response to infection, retaining iron 
in macrophages that would otherwise be released into plasma, 
and decreasing plasma iron concentration. Unfortunately, this 
diversion of iron from the circulation into stores limits the 
availability of iron for erythroid progenitor cells and results in 
iron-restricted erythropoiesis and the development of anaemia.
The bone marrow in infection
In anaemia, there is usually an increased production of Epo to 
stimulate bone marrow production of red cells to compensate 
for the anaemia, and the Epo response is commensurate with 
the degree of anaemia. This is not the case in the AI, where the 
Epo response is inadequate for the degree of anaemia, as has 
been reported in tuberculosis.11 This is a cytokine-mediated 
effect, as described above. It is not clear which of the two 
factors, limitation of the iron supply or inadequate Epo, is the 
major rate-limiting factor in the pathogenesis of the AI.
Whereas the diversion of iron from the plasma can be seen 
as a defence mechanism to deprive iron from the invading 
bacteria, the reason for the reduced Epo production and 
response of erythropoiesis to Epo that is associated with 
infection is not clear. One possible explanation is that this 
action at the marrow level limits the deleterious effect of the 
iron deprivation to erythropoiesis, which is set at a lower 
level, more commensurate with the available iron supply. This 
may explain why iron deficient anaemia does not develop in 
all infected subjects, and why the AI is less often microcytic/
hypochromic than normocytic/normochromic. It could be 
argued that with a normal level of erythropoiesis in the 
marrow, the anaemia could not be corrected in the absence of 
an adequate supply of iron. 
Red cell life span in infection
The moderate shortening of the red cell life span in AI due to 
the damage inflicted on the red cells by increased TNF-α is not 
regarded as a major factor in the pathogenesis of the anaemia. 
However, as the marrow cannot respond adequately to the 
shortened red cell survival because of impaired Epo production 
and the ability of the red cell progenitors to respond to Epo, it 
is an aggravating factor contributing to the anaemia.
The various factors that play a role in the pathogenesis of the 
anaemia of infection are illustrated in Fig. 1.
Diagnosis
Clinically the anaemia may be manifest by pallor, and result 
in weakness and fatigue. The anaemia is generally mild to 
moderate, with the haemoglobin concentration 8 - 9 g/dl, 
and the severity correlates roughly with the activity of the 
associated infection. The anaemia is usually normocytic, 
with normal mean cell volume (MCV), and normochromic 
with normal mean cell haemoglobin (MCH), but in 20 - 
50% of patients it is mildly microcytic (reduced MCV) and 
hypochromic (reduced MCH).  Marked hypochromia and 
microcytosis are unusual and generally indicate an associated 
abnormality such as iron deficiency or thalassaemia. The 
reticulocyte count is low for the degree of anaemia, indicating 
inappropriate production of red cells to compensate for the 
anaemia.
The diagnosis of AI can usually be confirmed by the changes 
























Fig. 1. The pathogenesis of the anaemia of infection
(IL-1 = interleukin-1; IL-6 = interleukin-6;
TNF- = tumour necrosis factor-alpha; INF – = interferon-gamma;
Fe = iron; Epo = erythropoietin).
Fig. 1. The pathogenesis of the anaemia of infection (IL-1 = 
interleukin-1; IL-6 = interleukin-6; TNF-α = tumour necrosis factor-
alpha; INF – γ = interferon-gamma; Fe = iron; Epo = erythropoietin).
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concentration normal to low, and transferrin saturation low 
to normal. Serum ferritin is raised as part of the acute-phase 
reaction.12 
Differentiation of the anaemia of 
infection from iron deficiency anaemia
When the AI is microcytic and/or hypochromic, it is important 
to distinguish it from iron deficiency anaemia (IDA), as iron 
therapy is contraindicated in AI but necessary in IDA. In 
both AI and IDA, the serum iron concentration is decreased. 
Serum transferrin is usually high in IDA, but low in AI. In 
IDA the reduced serum iron with raised transferrin results in 
low percentage transferrin saturation (serum iron divided by 
transferrin), whereas in AI, both serum iron and transferrin are 
reduced, so that saturation is either normal, or only slightly 
reduced. Serum ferritin is typically low in IDA but raised in AI, 
as part of the acute-phase reaction. 
Differentiation between IDA and AI can usually be made 
on the basis of the above tests, but may at times be difficult. 
In that situation, some of the newer tests of iron status may 
be of value in the differentiation of IDA and AI, in particular 
measurement of serum-soluble transferrin receptors (sTfr) and 
red cell zinc protoporphyrin (ZPN). sTfr are responsible for the 
uptake of transferrin-bound iron by cells in the bone marrow, 
and increase with iron deficiency. Serum sTfr, unlike ferritin, 
are not usually affected by infection, and are therefore useful 
in the differentiation of AI from IDA.13  More recent studies, 
however, suggest that the differentiation is not always absolute, 
as sTfr may sometimes increase with infection.14
In iron deficiency, with insufficient iron to insert into 
protoporphyrin to make haem, zinc is incorporated into 
protoporphyrin instead of iron. Thus ZPN increases in iron 
deficiency. Measurement of ZPN may be of value in the 
differentiation of IDA and AI, as the concentration does not 
increase in infection, but as with sTfr, this is not always the 
case.
Other tests of value in the differentiation include 
measurement of C-reactive protein and the ESR, which 
are usually raised in bacterial infection but normal in 
uncomplicated iron deficiency. 
In iron deficiency, tissue iron stores are depleted, while in 
infection they are normal or increased due to the diversion of 
iron from plasma to stores. Determination of iron stores will 
therefore usually differentiate IDA from AI, and is probably 
the gold standard for the distinction of the two entities. Iron 
stores in the reticuloendothelial system (RES) can be assessed 
directly by staining a bone marrow aspirate for iron. However, 
bone marrow aspiration is an invasive procedure, and is rarely 
indicated, and then only when all other tests fail to make the 
distinction. Despite being semi-quantitative and somewhat 
subjective, assessment of iron in a bone marrow aspirate 
remains the best determinant of the presence or absence of 
iron deficiency. Finally, response to iron supplementation is 
considered the ultimate diagnostic test for iron deficiency.
Combined anaemia of infection and 
iron deficiency 
The detection of concomitant iron deficiency in patients 
with AI, a combination that is not uncommon, is usually 
difficult. The specificity for iron deficiency of the transferrin 
concentration and percentage saturation is poor when there 
is associated infection. Low serum ferritin, the hallmark of 
iron deficiency, is also of limited value in the detection of 
iron deficiency in infection, because of the rise in ferritin 
Table I. Haematological and biochemical changes in anaemia of infection, iron deficiency anaemia and combined infection 
and iron deficiency
        Combined 
    Anaemia of Iron deficiency infection/
    infection  anaemia  iron deficiency
Haematology   
Haemoglobin   ↓  ↓  ↓
MCV    N or ↓  ↓  ↓
MCH    N or ↓  ↓  ↓
RCC    ↓  ↓ or N  ↓ 
Marrow iron   N or ↑  ↓  ↓
ESR    ↑  N  ↑
Biochemistry     
Iron    ↓  ↓  ↓
Transferrin   ↓ or N  ↑  ↓
Transferrin saturation  ↓  ↓  ↓
Ferritin    N or ↑  ↓  N or ↓
Soluble transferrin receptor  N  ↑  N or ↑
Zinc protoporphyrin  N or ↑  ↑  N or ↑
CRP    ↑  N  ↑
MCV = mean cell volume; MCH = mean cell haemoglobin; RCC = red cell count; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; N = normal.
Pg 1165-1168.indd   1167 11/2/07   10:23:27 AM
November 2007, Vol. 97, No. 11  SAMJ
ORIGINAL ARTICLES
1168
in infection. Thus in IDA with infection, serum ferritin 
concentration may be towards the lower end of the reference 
range, but not frankly abnormal. Patients with ferritin 
concentrations as high as >50 µg/l may be iron deficient, 
although those with concentrations >100 µg/l are usually iron 
replete. 
The changes in these various tests in AI, IDA and 
combined AI and IDA are summarised in Table I. Whereas 
the identification of concomitant iron deficiency in some 
of the anaemias of inflammation, e.g. that which occurs in 
rheumatoid arthritis has significant clinical implications due 
to the value of therapeutic iron, it is probably of much less 
significance in the anaemia of bacterial infection, in which the 
use of therapeutic iron is at best controversial, and at worst 
detrimental by exacerbating the infection. It is for this reason 
also that a therapeutic trial of iron, the ultimate diagnostic test 
for iron deficiency, is not feasible when there is infection.
Treatment
Treatment of the AI is primarily the treatment of the 
underlying infection with appropriate anti-infective therapy. 
Treatments aimed specifically at correcting the anaemia have 
varied. Where a cure of the underlying infection is impossible, 
transfusions for rapid correction of haemoglobin levels and 
human recombinant Epo (rhEpo) can be used with varying 
success.
Red cell transfusion in the presence of ongoing infection 
is usually only a temporary expedient that elevates the 
haemoglobin concentration in the short term, but does not 
address the underlying disorder. Red cell transfusion is 
indicated in life-threatening anaemia (Hb <6.5 g/dl) or when 
anaemia is particularly severe (Hb <8.0 g/dl). In general, red 
cell transfusions should be used to maintain the haemoglobin 
concentration at 7.0 g/dl or greater. 
The role of therapy with rhEpo in AI is largely untried and is 
not recommended as a specific treatment for the AI. There is no 
detailed literature on its use specifically in infections other than 
HIV. In one report,3 the administration of rhEpo to patients 
with osteomyelitis receiving parenteral antibiotics significantly 
decreased the need for red cell transfusions. 
Treatment with iron is contraindicated in uncomplicated 
AI. The use of iron when IDA is present in addition to AI is 
controversial, owing to the promotion of bacterial growth by 
iron. In general, iron therapy should only be considered if there 
is severe concomitant iron deficiency. Treatment should be 
with oral iron only and never with parenteral iron due to the 
possible aggravation of infection by a large bolus of iron. 
Vitamin B12 and folic acid have no place in the treatment of 
AI, unless there is clear evidence of concomitant deficiency. 
Folic acid should not be given to patients receiving antibiotic 
treatment with sulphasuxazole-trimethoprim. This antibiotic 
exerts its antibacterial effect by inhibition of folate synthesis in 
bacteria, an action that may be bypassed by the provision of 
pharmacological doses of folic acid.
The recognition of the pivotal role of hepcidin in iron 
metabolism and in the pathogenesis of AI could lead to the 
development of inhibitors of hepcidin for clinical use. Such 
hepcidin antagonists could be expected to release the iron 
sequestered in stores, restore the supply of iron to the marrow 
and improve the anaemia. However, the release of iron could 
aggravate the infection, thus triggering a therapeutic dilemma. 
Of interest also is the report that alcohol reduces levels of IL-6, 
and thus would be expected to reduce the hepcidin effect and 
possibly reduce the degree of anaemia.15 
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